全基因组关联研究 - - 驱动药物重新定位用于治疗失眠
Rahmat Dani Satria1, Wirawan Adikusuma2, Usi Sukorini1
1Department of Clinical Pathology and Laboratory Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia; Integrated Laboratory Installation, Dr. Sardjito General Hospital, Yogyakarta 55281, Indonesia.
Journal, genetic engineering & biotechnology
|May 20, 2025
概括
这项研究通过分析遗传数据和重新利用现有药物来确定潜在的失眠药物标. NRXN1被强调为开发新的失眠治疗的有希望的目标.
科学领域:
- 遗传学和生物信息学 遗传学和生物信息学
- 药理学 药理学是指药理学的学科.
- 睡眠医学 睡眠医学
背景情况:
- 失眠是一种广泛存在的睡眠障碍,具有重大的健康和经济后果.
- 目前对失眠的药理疗法有限,这推动了对新药发现方法的需求.
- 这项研究符合联合国可持续发展目标3:良好的健康和福祉.
研究的目的:
- 通过综合基因网络分析和基因组数据,确定失眠的新型治疗点.
- 通过生物信息学策略发现潜在的药物重用候选人治疗失眠.
- 探索已识别的基因的生物相关性及其与现有药物的相互作用.
主要方法:
- 从GWAS目录中检索了3,952个与失眠相关的单核酸多态 (SNP).
- 通过将SNP与亚洲人群中的近位变异联系起来,确定了1,765个失眠风险基因 (r2 ≥ 0.8),使用HaploReg v4.2.2.
- 采用生物信息学管道,使用功能注释和药物基因相互作用分析 (DGIdb) 来优先确定目标并识别重用药物.
主要成果:
- 确定了27个具有生物学意义的失眠风险基因和7个可用药物的目标.
- 发现了12种现有的药物,有可能用于治疗失眠.
- 突出NRXN1作为一个关键的目标,与杜洛西丁化和尼古丁波拉克里莱克斯相互作用,由于强大的功能评分.
结论:
- 生物信息学驱动的基因网络分析是有效的,用于识别药物重用候选人失眠.
- NRXN1调制为新型失眠疗法提供了一个有前途的途径.
- 进一步的实验验证对于确认NRXN1在治疗失眠方面的治疗潜力至关重要.
相关概念视频
01:19Management of Insomnia
229
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
229
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
138
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
138
01:23Antidepressant Drugs: MAOIs and Other Agents
173
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
173
01:23Sedatives and Hypnotics: Overview
243
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
243
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
167
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
167
01:14CNS Depressants: Barbiturates and Benzodiazepines
190
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
190